drugset / Trial / NCT01859143

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01859143

Phase 4 Completed 300 enrolled MedImmune LLC AstraZeneca · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This prospective annual release study is designed to evaluate the safety on new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2013-2014 influenza season.

Timeline

Start
2013-05
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza Virus Vaccine Vaccine 1e+07 unknown Intranasal

Indications